Topics:

Booming Regeneron adds to R&D footprint in NY

Tools

With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron ($REGN) needs some more space. Monday, it launched construction of a 300,000-square-foot R&D facility at its campus in Westchester County, NY. The company plans to move its scientists to the new center in 2015; in the meantime, they'll be working on expanding Eylea's label and bringing rheumatoid arthritis and cholesterol prospects to market. More